Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Frontier Communications Stock is Tumbling On Lackluster Q1 Results: Here’s The Details

Frontier Communications Parent, Inc (NASDAQ:FYBR) reported a first-quarter FY23 revenue decline of 0.5% year-on-year to $1.44 billion, beating the consensus…
byAnusuya Lahiri
May 5, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Frontier Communications Parent, Inc (NASDAQ:FYBR) reported a first-quarter FY23 revenue decline of 0.5% year-on-year to $1.44 billion, beating the consensus of $1.43 billion.
  • The growth in consumer, business, and wholesale fiber was more than offset by copper footprint and subsidy declines. 
  • Consumer revenue was $761 million, a 1.9% decline Y/Y, and Consumer fiber revenue rose by 10.1% Y/Y to $448 million.
  • Consumer fiber broadband revenue increased 17.3% Y/Y to $298 million, driven by growth in fiber broadband customers.
  • Business and wholesale revenue was $657 million, a 1.4% decline Y/Y, while the Business and wholesale fiber broadband revenue was $281 million, a 6% growth Y/Y.
  • Frontier built fiber to 339,000 locations, bringing total fiber passings to 5.5 million. Consumer fiber broadband net adds were 84,000, resulting in fiber broadband customer growth of 19.5%.
  • The adjusted EBITDA margin expanded by 80 bps to 36%.
  • EPS of $0.01 missed the consensus of $0.09.
  • Frontier held $2.0 billion in cash and equivalents and used $(765) million in free cash flow.
  • Outlook: Frontier reiterates FY23 adjusted EBITDA of $2.11 billion – $2.16 billion and targeted fiber builds to 1.3 million new locations.
  • Price Action: FYBR shares traded lower by 12.70% at $18.74 on the last check Friday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

By Jelena Martinovic
May 16, 11:25 AM
Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."

ENVB